Law360, New York (May 03, 2012, 2:04 PM ET) -- The United States Supreme Court has again reversed the Federal Circuit, ruling unanimously that a generic drug manufacturer may file a counterclaim to force correction of an overbroad use code that encompasses unclaimed methods of using the drug at issue.
In interpreting the text of 21 U.S.C. § 355(j)(5)(C)(ii)(I), the court in Caraco Pharmaceutical Laboratories Ltd. v. Novo Nordisk A/S, No. 10-844, 566 U.S. __ (2012), gave substantial weight to ensuring that the U.S. Food and Drug Administration fulfill its statutory duty to approve noninfringing generics...
Takeaways From Caraco V. Novo Nordisk
To view the full article, take a free trial now.
